Search results
Showing 1831 to 1845 of 2208 results for guidelines
Transobturator foramen procedures for stress urinary incontinence (IPG107)
The National Institute for Health and Clinical Excellence (NICE) issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on transobturator foramen procedures for stress incontinence in January 2005. This guidance has been withdrawn as the use of this procedure is now covered in NICE guideline CG40. NICE has no plans to carry out further assessment of this procedure under the Interventional Procedures Programme.
PICO negative pressure wound dressings for closed surgical incisions (HTG509)
Evidence-based recommendations on PICO negative pressure wound dressings for closed surgical incisions.
Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis (HTG521)
Evidence-based recommendations on enzyme-linked immunosorbent assay (ELISA) tests for therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors in rheumatoid arthritis. The tests are Promonitor, IDKmonitor, LISA-tracker, RIDASCREEN, MabTrack, and those used by Sanquin Diagnostic Services.
Discontinued Reference number: GID-SGWAVE0702
Discontinued Reference number: GID-SGWAVE0761
Discontinued Reference number: GID-SGWAVE0700
Evidence-based recommendations on cemiplimab (Libtayo) with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer in adults.
Discontinued Reference number: GID-SGWAVE0762
Discontinued Reference number: GID-SGWAVE0701
Secukinumab for treating non-radiographic axial spondyloarthritis (TA719)
Evidence-based recommendations on secukinumab (Cosentyx) for treating non-radiographic axial spondyloarthritis in adults.
Evidence-based recommendations on bevacizumab (Avastin), with other drugs, for treating metastatic colorectal cancer in adults.
Relugolix for treating hormone-sensitive prostate cancer (TA995)
Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with paclitaxel or nab-paclitaxel for triple-negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.
Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults.
AmnioSense for unexplained vaginal wetness in pregnancy (MIB198)
NICE has developed a medtech innovation briefing (MIB) on AmnioSense for unexplained vaginal wetness in pregnancy .